Metastasis is responsible for most cancer deaths. Despite extensive research, the mechanistic understanding of the complex processes governing metastasis remains incomplete. In vivo models are paramount for metastasis research, but require refinement. Tracking spontaneous metastasis by non-invasive in vivo imaging is now possible, but remains challenging as it requires long-time observation and high sensitivity. We describe a longitudinal combined radionuclide and fluorescence whole-body in vivo imaging approach for tracking tumor progression and spontaneous metastasis. This reporter gene methodology employs the sodium iodide symporter (NIS) fused to a fluorescent protein (FP). Cancer cells are engineered to stably express NIS-FP followed by selection based on fluorescence-activated cell sorting. Corresponding tumor models are established in mice. NIS-FP expressing cancer cells are tracked non-invasively in vivo at the whole-body level by positron emission tomography (PET) using the NIS radiotracer [ . PET is currently the most sensitive in vivo imaging technology available at this scale and enables reliable and absolute quantification. Current methods either rely on large cohorts of animals that are euthanized for metastasis assessment at varying time points, or rely on barely quantifiable 2D imaging. The advantages of the described method are: (i) highly sensitive non-invasive in vivo 3D PET imaging and quantification, (ii) automated PET tracer production, (iii) a significant reduction in required animal numbers due to repeat imaging options, (iv) the acquisition of paired data from subsequent imaging sessions providing better statistical data, and (v) the intrinsic option for ex vivo confirmation of cancer cells in tissues by fluorescence microscopy or cytometry. In this protocol, we describe all steps required for routine NIS-FP-afforded non-invasive in vivo cancer cell tracking using PET/CT and ex vivo confirmation of in vivo results. This protocol has applications beyond cancer research whenever in vivo localization, expansion and long-time monitoring of a cell population is of interest.
Introduction
Metastatic disease is the cause for most cancer-related deaths 1 . Despite extensive research into metastatic processes, reliable monitoring of cancer metastasis in animal model systems is difficult to achieve. Recent advances in whole-body imaging technologies and multi-modal imaging approaches have enabled non-invasive in vivo cell tracking 2, 3, 4, 5 . The latter can be used as a tool to monitor the presence, distribution, quantity, and viability of cells, non-invasively and repeatedly in a live animal or a human.
The purpose of the method described here is to longitudinally and non-invasively track cancer cells in 3D in living rodent tumor models. Using this method, researchers will be able to accurately quantify tumor progression including metastatic spread in 3D. Compared to traditional nonimaging-based techniques, this method offers the acquisition of quantitative data with largely reduced animal numbers. Another feature of this method is that it allows correlation of in vivo imaging with streamlined downstream ex vivo analysis of the tracked cells in harvested tissues by histology or cytometry 3, 6 .
The rationale for the development of this method was to provide an in vivo tool for the monitoring and quantification of the whole metastatic process in rodent tumor models. Importantly, it was designed to minimize animal use while at the same time reducing inter-animal variability. Longitudinal non-invasive whole-body imaging is excellently suited to inform on metastatic outgrowth, for which per se it is difficult to predict accurately the time and location of its occurrence. Whole-body 3D imaging has therefore been at the center of method development. To close the scale gap between whole-body in vivo imaging and potential downstream ex vivo histological confirmation, a multi-scale imaging approach based on a dual-mode radionuclide-fluorescence reporter was adopted . Fluorescence whole-body imaging has been used for the acquisition of 3D images, but it is much less sensitive compared to bioluminescence or radionuclide technologies 2 . Nonetheless, fluorescence offers the opportunity to perform ex vivo downstream tissue analysis by cytometry or microscopy. The latter closes the scale-gap between macroscopic whole-body imaging (mm resolution) and fluorescence microscopic tissue analysis (µm resolution) 3 . Therefore, radionuclide and fluorescence modalities complement each other, ranging from the whole-body level to the (sub-)cellular scale.
Reporter gene imaging is ideally suited for prolonged cell tracking as required in metastasis research. In this application it is superior to direct cell labeling as it is (i) not affected by label dilution and thus not limited in tracking time, and (ii) better reflects live cell numbers. Consequently, wholebody cell tracking is particularly useful for applications in which traceable cells proliferate or expand in vivo, for example in cancer research 3, 6 , for the detection of teratoma formation in stem cell research, or for the quantification of immune cell expansion 5 .
Various radionuclide-based reporter genes are available 2 . These include enzymes such as the herpes simplex virus HSV11 thymidine kinase (HSV1-tk), transporters such as the sodium iodide symporter (NIS) or the norepinephrine transporter (NET), as well as cell surface receptors such as the dopamine D2 receptor (D2R). NIS is a glycosylated trans-membrane protein that actively mediates iodide uptake, for example in follicular cells in the thyroid gland for the subsequent synthesis of thyroid hormones 10 . This process is driven by the symport of Na + and relies on the cellular sodium gradient, which is maintained by the Na . Consequently, NIS better reflects living cell numbers than other reporters as iodide/radiotracer uptake is linked to an active Na + /K + gradient rather than the mere presence of the transporter. Traditionally, radioiodide has been used for NIS imaging. For cell tracking, alternative NIS radiotracers that are not metabolically entrapped in the thyroid have been reported to be superior 6 . . The second method is through addition of 18 F to non-radioactive boron trifluoride 14 . The latter method was reported to yield higher specific activities 14 and is the method of choice for preclinical imaging.
NIS is highly expressed in the thyroid tissues. It is also expressed in the salivary, lachrymal and lactating mammary glands as well as the stomach, but at lower levels as compared to the thyroid gland 10 . Therefore, excellent contrast imaging in other body regions can be achieved using NIS. It is also highly homologous between human, rat and mouse 10 . Moreover, there are no reports of toxicity upon ectopic NIS expression in non-thyroidal cells. Importantly, NIS has also not been associated with host immune responses, neither in humans nor in rodents. NIS has been used as a reporter gene to measure promoter activity 15, 16, 17 and gene expression 18, 19, 20, 21, 22, 23 in several different contexts. It has also been used for non-invasive imaging of gene therapy vectors 24, 25 , and to track cells in cardiac 4 , hematopoietic 26 , inflammation 5 , and neural studies 27 . Recently, NIS has also been used as a reporter gene to track cancer metastasis in vivo 3, 6 . In summary, the main advantages of this method over previous techniques are: (i) highly sensitive non-invasive 3D in vivo localization and quantification of metastatic spread, (ii) automated production of [ 18 F]BF 4 -at high molar activities, (iii) a significant reduction in required animals through longitudinal imaging, (iv) the acquisition of paired data from subsequent imaging sessions resulting in improved statistical data, which in turn further reduces animal use, and (v) the intrinsic option for ex vivo confirmation of cancer cells in tissues by cytometry or fluorescence microscopy.
Protocol
This protocol meets all requirements set by United Kingdom (UK) legislation and the local Ethical Review panel. When following this protocol, ensure the procedures also meet all requirements dictated by national legislation and local Ethical Review panel. Ensure every experiment involving radioactivity is compliant with legislation and local rules and performed safely.
Engineering and characterization of cancer cells to express the radionuclidefluorescence fusion reporter NIS-FP
NOTE: For simplicity, mEGFP A206K is abbreviated as "GFP", and mCherry as "RFP" in the subsequent sections of this protocol.
1. Generation of lentiviral particles 1. To produce lentivirus particles, co-transfect 293T cells with the following four plasmids using a suitable transfection method: (i) the reporter gene encoding plasmid (pLNT SFFV NIS-GFP or pLNT SFFV NIS-RFP (see Supplementary Information), (ii) the thirdgeneration lentiviral packaging plasmids pRRE and (iii) pRSV-Rev, and (iv) a virus envelope containing plasmid, e.g, pMD2.G. Pre-mix plasmids before adding them to the transfection mix. Perform transfection in a cell culture hood. NOTE: Additional transfection information is provided in Supplementary Information. 2. Assess transfection success after 48 h by standard wide-field fluorescence microscopy with filter settings appropriate for the chosen fusion reporter (NIS-GFP or NIS-RFP). NOTE: Fluorescence signals are indicative of reporter gene transfection and therefore only a surrogate for successful co-transfection, not an indicator of successful virus production. 3. Harvest the virus particle-containing supernatant using a syringe and remove floating cells and cell debris by filtering through a 0.45 µm sterile polyethersulfone (PES) filter. Transfer to a sterile 1.5 mL polypropylene reaction tube. Perform virus work in a cell culture hood and ensure no live virus leaves the contained environment. . 2. Confirm reporter integrity by standard immunoblotting as described elsewhere 29 .
3. Analyze intracellular fusion reporter localization by confocal fluorescence microscopy. NOTE: Staining with or co-expression of a plasma membrane marker 6 and subsequent co-localization analysis 30 will facilitate this step. F addition to boron trifluoride is described. Users of a more widely available ARS platform (see Table of (Table  1) as well as a detailed description of each step in the XML sequence file ( Table 2) to support translation to any other automated platform.
1. Set up the ARS platform as described in Table 1 13. Wash the reactor with water (approx. 5.5 mL). 14. Pass the resulting solution through the alumina and second anion exchange cartridges. 15. Rinse syringes S2 and S3 with water. 16. Wash the second anion exchange cartridge with water and dry it with nitrogen gas. 17. Elute the product (V19 to V20) with 1 mL of 0.9 % NaCl (V14) into syringe S3. 18. Transfer the product (400-500 µL) via the outlet line (V21) to a 1 mL glass collection vial. NOTE: Molar activity is an important aspect of every radiotracer. However, its routine determination is not only time-consuming but also requires significant amounts of the freshly synthesized [ , it is recommended to schedule a few dedicated test-runs for this purpose. For more details about molar activities, please refer to the Discussion section. , animals are imaged as described above, and then rested awake until the radioactivity has decayed sufficiently to be regarded as negligible, e.g. 48 h later when only 1.3·10 −6 % residual 18 F radioactivity will be present in the animal. In the subsequent imaging session, the competitive substrate ClO 4 -is administered at a dose of 200 mg/kg 30 min prior to radiotracer administration, and imaging is performed as described above.
In vivo imaging of NIS-FP expressing cells by nanoPET/CT
2. Imaging by nanoPET/CT 1. Set the desired CT imaging parameters, e.g. using the nanoPET/CT 55 kVp tube voltage, set the exposure time to 1200 ms with onedegree angular stepping and 180-degree projections. 2. Set the parameters for PET image acquisition. Use static scan PET parameters with a duration of 30 min, 1:5 coincidence mode and 400-600 keVp energy window. 3. At countdown time = 15 min start CT image acquisition. 4. At countdown time = 0 min start PET image acquisition.
1. If serial animal imaging is required, let animals fully recover from anesthesia, i.e. regain consciousness under supervision. Subsequently, transfer them to a maintenance unit. 2. If this is the terminal imaging session, proceed to animal euthanasia by either anesthetic overdose, rising concentration of carbon dioxide, or dislocation of the neck.
5.
In vivo data analysis 
Ex vivo analyses
Perform the listed downstream analyses: (i) fluorescence imaging of organs containing fluorescent cancer cells (primary tumor and metastases) during animal dissection, (ii) measurement of radiotracer tissue distribution, and (iii) histologic or (iv) cytometric assessment of cancerous organs.
1. Measurement of radiotracer distribution by γ-counting (ex vivo biodistribution) and ex vivo fluorescence imaging of cancerous tissues. 1. Measure radioactivity of the whole dead animal and note the value and the time.
2. Dissect the animals and harvest the following tissues: lung, heart, blood (using 20 mm glass capillaries), liver, stomach, kidneys, spleen, small and large intestines, thyroid and salivary glands, a piece of muscle from the leg, and bone of the rear femurs, and relevant and dissectible lymph nodes and cancerous tissues. 3. Measure the radioactivity of the remaining carcass first including then excluding the tail and note the values and the times of measurement. NOTE: Radioactivity in the tail can be considered stemming from radiotracer that was mis-injected and thus did not reach circulation; hence, this amount of radiotracer was not contributing to the injected dose. The tail radioactivity serves also as a retrospective parameter of injection quality. 4. Weigh all tissues (use pre-weighed tubes). 5. Take photographs of cancerous organs in daylight and under fluorescence light.
NOTE: Use a camera stand to keep the distance between camera lens and organ constant (or use a dedicated commercial instrument for this purpose). 6. Embed organs/tissues intended for downstream histology into OCT or immerse them in formalin for fixation. For other downstream applications sample preparation can differ. 7. Prepare radiotracer calibration standards in duplicate, e.g. 0 to 1000 kBq [ 2. Analyze cancerous tissues by cytometry or histology according to the user's preferences and standard protocols (as described elsewhere 3, 6, 28 ).
Representative Results
The first step requires genetic engineering of the cancer cells of interest. Here, the results of lentiviral transduction of metastatic murine inflammatory 4T1 breast cancer cells and human metastatic MDA-MB-231 cells with lentivirus particles carrying DNA encoding either NIS-GFP or NIS-RFP are shown. Transduction efficiencies varied between cancer cell lines (Figure 2A, left column) . However, all resultant transduced cancer cell lines were selected by FACS to purity (Figure 2A, right) . Confocal fluorescence microscopy ( Figure 2B ) demonstrated correct plasma membrane localization of NIS-FPs. NIS-FP function was quantified using NIS-afforded radiotracer uptake (Figure 2C-2E ) and demonstrated NIS function and specificity. Notably, no significant differences between 4T1.NIS-GFP and 4T1.NIS-RFP expressing cell lines with similar NIS expression levels were found ( Figure 2C ). Following full in vitro cell line characterization, tumor models were set up with the newly generated traceable cancer cell lines. As an example, the 4T1.NIS-GFP tumor model, a model for inflammatory breast cancer, is shown here (Figure 3) . In tumor-bearing animals longitudinal wholebody PET imaging then informed on tumor progression including metastatic spread ( Figure 3B) On day 19 after tumor inoculation, the primary tumor was clearly identified using PET, but found no metastases. Ten days later (day 29), the same tumor-bearing mice were re-imaged and distant metastasis at various locations in all animals (lung metastasis, metastasis to various inguinal and/or axillary lymph nodes) were identified. The example in Figure 3 showed extensive lung metastasis with several clearly identifiable and quantifiable nodules in the lung (Figure 3B-3E) . Moreover, the animal presented with regional spread of the tumor into the peritoneal wall as well as metastasis to the inguinal and both axillary lymph nodes. %ID values of individual metastases in the lung ( Figure 3E ) differed widely, but so did the occupied volumes of the underlying metastatic nodules. In contrast, volume-normalized %ID/mL values ( Figure 3E) were much more uniform. This was comprehensible for different metastases at similar development stages (i.e. developed between days 19 and 29; Figure  3B ). In contrast, the normalized %ID/mL value for the primary tumor was lower than those for the lung metastases, which is in line with a tumor mass that had more time to progress and remodel including the influx of other cell types (stromal cells, immune cells), particularly in this model of inflammatory breast cancer.
Copyright
Guided by in vivo images and the fluorescence of cancer cells (visible during animal dissection under fluorescence light), small deep-seated organs such as lymph nodes were reliably harvested and, at the same time, assessed for cancerous nodule content ( Figure 4A ). While the fluorescence signal during animal dissection was indicative of tumor cell presence, it was important to ensure this classification was accompanied by ex vivo radioactivity measurements of the harvested tissues. Figure 4B shows the standard uptake values (SUV) obtained for the various tissues across a cohort of three animals, all of which presented with metastasis. Endogenously NIS-expressing organs such as the thyroid and salivary glands (harvested combined) or the stomach also showed the expected high radiotracer uptake. Furthermore, this NIS-FP approach allowed straightforward cancer cell identification during histology ( Figure 4C ). This immunofluorescence histology example data showed tumor vascularization in the 4T1.NIS-GFP tumor model. This data also showed that the NIS-GFP reporter resided predominantly in the plasma membranes of the tumor cells also in vivo (Figure 4C) , thereby validating the uptake results. Figure 3 . The primary tumor was harvested, embedded in OCT and frozen before being sectioned (10 µm) and processed for staining. NIS-GFP expressing cancer cells were directly identified without the need for antibody staining. Blood vessels were stained with a rabbit antibody against mouse PECAM-1/CD31 (2 µg/mL) and a Cy5-conjugated goat anti-rabbit secondary antibody. Nuclei were stained with 2'-(4-ethoxyphenyl)-5-(4-methyl-1-piperazinyl)-2,5'-Bi-1H-benzimidazole (1 µg/mL) and the sample mounted in poly(vinyl alcohol -vinyl acetate) containing 2.5 % (w/v) Dabco as an antifade. Confocal images were obtained using a confocal microscope with settings appropriate for 2'-(4-ethoxyphenyl)-5-(4-methyl-1-piperazinyl)-2,5'-Bi-1H-benzimidazole, GFP and Cy5. These example data clearly show that the 4T1.NIS-GFP tumor is vascularized but also that vascularization differs in its extent (cf. top left with bottom middle). It also shows that the NIS-GFP reporter predominantly resides in the plasma membranes of the tumor cells in vivo (inset), thereby validating the in vitro uptake results. Please click here to view a larger version of this figure. volume is > 5 mL, pause the sequence at step 37, return to step 26, fully insert the needle into the vial containing 18 F, and resume the process. [40] Close the [ Pressurize the eluent vial in position V2 [42] [43] [44] Open reactor valve V8, aspirate eluent from V2 into syringe S1
[45-50] Elute QMA cartridge C1 into reactor (V8) using saline from syringe S1, set the reactor temperature to 90 °C 
Discussion
The first step to render cancer cells traceable in vivo by this method requires engineering them to express the NIS-FP fusion reporter. The choice of the fluorescent protein in the fusion reporter is critical as oligomerizing fluorescent proteins can lead to artificial reporter clustering, thereby negatively affecting its function. We have had success with proven monomeric fluorescent proteins such as mEGFP (with the monomerizing mutation A206K 36, 37 ), mTagRFP, or mCherry. NIS can either be of human or mouse origin (hNIS or msNIS) depending on the purpose of the experiment and the cancer model. Transduction efficiencies generally vary between different cancer cell lines. However, generated cancer cell lines are subsequently purified by FACS in this protocol, thereby reducing the need for optimizing transduction conditions. Transduction with high multiplicity of infection is not always advisable as multiple construct integration into the genome is likely to result not only in higher construct expression but also in more unwanted/unregulated genome modification. Therefore, it is important to let polyclonal transduced cells grow to stability of expression (monitored by flow cytometry) and avoid sorting the brightest clones only by FACS. It also renders functional validation of non-reporter features crucial before these cells should be used for in vivo experiments. A recently developed alternative to viral gene delivery is gene editing technology 38 , which offers more specific control over viral integration sites. Expression analysis by flow cytometry and immunoblotting is important. Flow cytometry allows acquisition of population-based single cell data, for example to examine whether there is any drift in reporter expression levels over time. It relies on the FP moiety only, unless cells are also stained with an antibody directed against surface or total NIS. Flow cytometry does not inform on fusion reporter integrity. In contrast, immunoblotting reports on the integrity of the fusion reporter. The molecular weight of NIS and the FP must be added to determine the expected molecular weight of the chosen NIS-FP. Confocal fluorescence microscopy demonstrated fusion reporter colocalization with the plasma-membrane marker wheat germ agglutinin in all newly made cell lines. This was the expected cellular location for most of the protein and indicated a go-ahead milestone for subsequent functional validation. If minimal/no NIS-FP was found on the plasma membrane (e.g. only in internal cellular compartments), this would indicate a cell biological issue with the fusion reporter in this cell line, or a potential mutation of the fusion reporter affecting its intracellular trafficking. It is noteworthy that we have not observed such a case in any of the cancer cells we tested so far, which included: A375P, A375M2, SK-Mel28, WM983A/B (human melanoma); MCF-7, MDA-MB-231, MDA-MB-436 (human breast cancer); NCI-H1975 (human lung cancer); SK-Hep1 (human liver cancer); 4T1, 4T1.2, 66cl4, 67NR, FARN168 (murine inflammatory breast cancer); B16F0, B16F3, B16F10 (murine melanoma); MTLn3 (rat breast adenocarcinoma).
NIS function must be measured using uptake assays with radioactive NIS substrates. Due to the SPECT radiotracer 99m TcO 4 -being generatorproduced and therefore widely available in hospitals without the need for any radiotracer synthesis as well as having a more convenient longer half-life (6.01 h for 99m
Tc as compared to 110 min for 18 F), we used this NIS substrate for routine functional validation of new NIS-FP expressing cell lines. Pre-blocking of NIS-expressing cells with the NIS co-substrate sodium perchlorate resulted in the expected reduction/abolishment of radiotracer uptake, thereby demonstrating specificity of radiotracer uptake. This NIS specificity test is a critical validation step. If a NIS specificity experiment would not result in reduced radiotracer uptake comparable to the respective parental cells, either a technical error during the experiment has occurred, or the radiotracer uptake was not due to NIS. It is also possible that sodium perchlorate pre-blocking reduces radiotracer uptake in a parental cell line; this would identify cell lines with endogenous functional NIS expression (e.g. stimulated thyroid cells 6 ).
A crucial advantage of this imaging protocol is that information is collected in 3D and over time. This allows the comparison of images from the same animal over time, thereby providing paired data and thus overcoming the issues caused by inter-animal variability. This contrasts with most non-imaging related metastasis assessment methods that are based on sacrificing different animals at different time points. In Figure  3B it is evident how metastatic spread and outgrowth progressed over time in an individual animal. The signals detected by PET/CT imaging are fundamentally caused by NIS expression. This includes all signals from exogenously NIS-expressing cancer cells as well as all organs endogenously expressing NIS. Typical endogenous NIS signals are found in thyroid and salivary glands, the stomach, and, at low levels in some parts of the mammary and lachrymal glands. In addition to endogenous NIS expression, the NIS radiotracer [
-is also excreted via the kidneys, thereby explaining radiotracer uptake in urine-filled bladders. Kidney uptake is no longer detectable at the imaging time point recommended in this protocol (45 min post radiotracer injection 6 ). If signals from urine-filled bladders should lead to signal-to-background issues, the bladder can be mechanically emptied under anesthesia before imaging. Importantly, the endogenous signals can vary between animal strains. It is also noteworthy that endogenous NIS expression in the mammary glands can be higher under lactating conditions 10 . In the presented case and in the cases of those metastatic cell lines successfully characterized before (cf. list above), we did not find endogenous NIS expression to significantly interfere with metastasis detection. It is noteworthy, that [ 18 F]BF 4 -remains more available for uptake into cancerous tissues as compared to iodide, because iodide is metabolized into thyroid hormones 6 . This phenomenon might also contribute to larger amounts of radioiodide in the blood stream as compared to [ . For different applications (cancer cell tracking in other cancers or non-cancer cell tracking applications), this might differ, and it is therefore recommended to assess whether endogenous NIS expression is likely to cause signal-to-background issues through preliminary experiments. An important aspect in preclinical imaging is the molar activity of the radiotracer. The method described here uses ~1. ; it is less important in the human setting 40 . High molar activities are therefore imperative for high-quality preclinical PET imaging. Molar activities obtained by the boron trifluoride addition method 14 , which is shown in its automated form in this protocol, overcome this issue. Furthermore, it is noteworthy that the presented protocol for [ PET/CT imaging allows the visualization of radiotracer uptake, which is indicative of NIS-mediated radiotracer uptake stemming from NIS-FP expressing cancer cells. More importantly, the associated PET signals can be quantified. It is necessary to apply reliable thresholding procedures to ensure a consistent and unbiased differentiation of relevant signals from any potential background. As the background varies in different locations in vivo, it is important to consider local/regional thresholding and segmentation. One such method was developed by and named after Otsu 34 , and its 3D implementation is employed for 3D rendering of the primary tumor and metastases in this protocol. Generally, the image seen by the observer visually corresponds best to the quantified %injected dose (%ID) values. As for image-based quantification, it is also important to normalize the measured radioactivity values of the different tissues to their volumes. There are two predominantly used ways of expressing normalized results, (i) %ID per volume (e.g. %ID/mL), and (ii) standard uptake value (SUV 35 ). They differ in that %ID/mL takes into account the individual volume only, while SUV is a measure that is relative to the average radioactivity across the whole animal. It is also important to note that NIS imaging renders the live tumor volume (LTV) accessible, because dead/dying cells not synthesizing ATP can no longer import radiotracer 10 . This explains the large low-signal area within the primary tumor ("donut shaped" tumor) indicating areas of tumor cell death/ necrosis. Importantly, LTV was a much more reliable measure of tumor burden as compared to the crude tumor volume accessible by caliper measurements (which does not take into account viability and assesses only superficial tumor regions).
A major advantage of this dual-mode tracking strategy is evident when harvesting tissues after animal culling. Guided by in vivo images and assisted by fluorescent cancer cells during animal dissection, small and deep-seated organs/metastases can also be reliably harvested. Frozen tissue preservation/sectioning methodology enables the direct fluorescence imaging of GFP without the need for staining with an anti-GFP antibody, but at the expense of reduced structural tissue preservation as compared to formalin-fixed paraffin-embedded methodology (FFPE). The latter critically requires also anti-FP staining, because the FFPE method is incompatible with intact preservation of fluorescent proteins (due to fixation/dehydration/rehydration). While the fluorescence signal is indicative of tumor cell presence, it is important to ensure this classification is confirmed by ex vivo radioactivity measurements of the harvested tissues ('biodistribution'). Ex vivo radioactivity measurements are more sensitive than visual detection of fluorescence, hence can allow the identification of cancer cell-dependent signals that would otherwise remain undetected. In the case of a terminal imaging session, it is critical to accurately note the injected radiotracer amounts as well as the times of radiotracer radioactivity measurements, animal injection, animal culling, and calibrated scintillation counter measurements of harvested tissues. This is crucial to ensure correction for radiotracer decay and thereby enable reliable biodistribution analysis.
PET/CT imaging enables repeated non-invasive 3D quantification of tumor progression including the assessment of metastatic spread on a whole-body level. This feature is a significant advantage over conventional methods, which often rely on large cohorts of animals that are euthanized for the assessment of tumor progression at varying time points. The advantages of this imaging-based approach are: (i) highly sensitive non-invasive 3D in vivo quantification, (ii) a significant reduction in animal numbers due to the possibility of repeat imaging, (iii) the acquisition of longitudinal paired data from subsequent imaging sessions improving statistics by excluding inter-animal variability, which in turn further reduces animal numbers, (iv) automated production of [ In vivo cell tracking is a growing field. It has been fueled by recent advancements in imaging technology, which resulted in enhanced resolution, detection limits and multiplex capability (via multi-modal imaging). In this protocol, we apply this concept to track tumor progression including spontaneous cancer cell metastasis in 3D by repeat imaging. Applications include studies aimed at unraveling the mechanisms of spontaneous cancer cell metastasis. For example, traceable tumor cells could be used to study the impact of different immune cell components (as present/ functional in animal strains of different levels of immunocompromisation) on the metastatic process. Similarly, the impact of individual genes, either in the animal strain or the cancer cell line, could be studied. Furthermore, the presented protocol could be used to assess/validate the efficacy of specific drugs or therapeutic concepts on tumor progression. Importantly, this reporter gene:radiotracer pair for PET imaging (NIS: [
18 F]BF 4 -) could also be used for different cell tracking applications. For example, several cell therapies are currently emerging as promising therapeutic approaches. This includes cellular therapeutics for cancer treatment 41 but also in transplantation 42 and regenerative medicine 43, 44 settings. Whole-body in vivo cell tracking is becoming increasingly important for the development and clinical translation of cellular therapeutics, for example, for evaluating safety and for therapy monitoring.
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